AI-Assisted vs Conventional Teleglaucoma Referral (GATES)
Artificial Intelligence-Assisted Teleophthalmology for Glaucoma Screening: A Randomized Controlled Trial
This randomized controlled trial will compare an artificial intelligence (AI)-assisted teleglaucoma referral pathway with conventional referral among adults identified with referable glaucoma through the Los Angeles County Department of Health Services (LAC DHS) Teleretinal Screening Program. The primary objective is to determine whether AI-assisted referral reduces time to in-office diagnosis of manifest glaucoma. Secondary outcomes include glaucoma severity, visual function, need for glaucoma surgery, patient-reported quality of life and satisfaction, health system resource utilization, and cost-effectiveness.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Participants identified with referable glaucoma during routine teleretinal screening will be randomized 1:1 to an AI-assisted referral pathway or a conventional referral pathway.
In the AI-assisted arm, fundus photographs will be analyzed using validated deep learning models integrated within the Eye-AI platform. AI outputs, together with intraocular pressure and other clinical information, will be used to stratify referral urgency. AI-generated recommendations will undergo review by glaucoma specialists before referral.
In the conventional referral arm, fundus images will undergo manual review by LAC DHS optometrists, with referral and prioritization performed according to current clinical practice.
Participants in both groups will undergo comprehensive in-office glaucoma evaluation following referral and will be followed for up to 36 months. The primary outcome is time from screening to in-office diagnosis of manifest glaucoma. Secondary outcomes will evaluate disease severity and visual function, need for glaucoma surgery, patient-reported quality of life and satisfaction, health system resource utilization, and cost-effectiveness.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Benjamin Y. Xu, MD, PhD
- Número de telefone: 323-442-6425
- E-mail: benjamix@usc.edu
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Provision of signed and dated informed consent
- Age ≥18 years
- Receiving routine teleretinal screening through the Los Angeles County Department of Health Services (LAC DHS) Teleretinal Screening Program
- Positive prediction for referable glaucoma by the validated AI algorithm at the time of screening
- No prior ophthalmology or optometry follow-up within the past year
- Willingness and ability to comply with study procedures and follow-up
Exclusion Criteria:
- Inability to tolerate fundus photography or ungradable fundus images
- Acute vision loss or major ocular complaints requiring immediate in-person evaluation
- Prior glaucoma diagnosis or treatment within the past year
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: AI-Assisted Teleglaucoma Referral
Participants will undergo AI-assisted referral using validated deep learning models integrated within the Eye-AI platform. AI outputs, together with intraocular pressure and other clinical information, will be used to stratify referral urgency. AI-generated recommendations will be reviewed by glaucoma specialists before referral. |
Fundus photographs acquired during routine teleretinal screening will be analyzed using validated deep learning models integrated within the Eye-AI platform. For participants identified with referable glaucoma, AI outputs will be combined with intraocular pressure and other clinical information to stratify referral urgency. All AI-generated recommendations will undergo review by a glaucoma specialist before referral. |
|
Comparador Ativo: Conventional Teleglaucoma Referral
Participants will undergo conventional teleglaucoma referral based on manual grading of fundus photographs by LAC DHS optometrists, with referral and prioritization performed according to current clinical practice. |
Fundus photographs will undergo conventional manual grading by LAC DHS optometrists, with referral and prioritization performed according to current clinical practice. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to in-office diagnosis of glaucoma
Prazo: From screening through 36 months
|
Number of days from the initial teleophthalmology screening to the first in-office glaucoma evaluation at which manifest glaucoma is diagnosed. |
From screening through 36 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Visual field mean deviation (MD)
Prazo: Baseline and 36 months
|
Glaucoma disease severity assessed using visual field mean deviation (MD), measured in decibels (dB), at baseline and 36 months. |
Baseline and 36 months
|
|
Visual field index (VFI)
Prazo: Baseline and 36 months
|
Glaucoma disease severity assessed using visual field index (VFI), expressed as a percentage (%), at baseline and 36 months. |
Baseline and 36 months
|
|
Mean retinal nerve fiber layer (RNFL) thickness
Prazo: Time Frame: Baseline and 36 months
|
Glaucoma disease severity assessed using mean retinal nerve fiber layer (RNFL) thickness measured by optical coherence tomography (OCT), expressed in micrometers (µm), at baseline and 36 months. |
Time Frame: Baseline and 36 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- APP-26-03722
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data will not be shared because patient-level health data from the Los Angeles County Department of Health Services (LAC DHS) are subject to HIPAA and LAC DHS data-sharing restrictions. Aggregate-level study results and derived analytic outputs will be shared in accordance with NIH policy and the approved Data Management and Sharing Plan.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .